Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Disturbances in Heart Rhythm

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026

Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026

Same author

Commentary: Transcatheter electrosurgery: Telsa's AC or Edison's DC? Only Time Will Tell.

JTCVS structural and endovascular·2026

Same author

Bioprosthetic valve fracture during valve-in-valve transcatheter aortic valve replacement: patient selection, procedural timing, and technical optimization.

Expert review of medical devices·2026

Same author

Bench Testing of a New, Semirigid, Saddle-Shaped, Complete Mitral Annuloplasty Ring Designed to Circularize During Transcatheter Mitral Valve-in-Ring Procedures.

Structural heart : the journal of the Heart Team·2026

Same author

Intra-Annular Versus Supra-Annular Self-Expanding Valves for Valve-in-Valve TAVR.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Search research articles

Related Experiment Video

Updated: May 23, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Simple amiodarone protocol reduces postoperative atrial fibrillation.

Keith B Allen¹, David A Heimansohn, Robert J Robison

¹Departments of Cardiothoracic Surgery, St. Vincent Hospital and Health Care Center, Indianapolis, IN.

Innovations (Philadelphia, Pa.)

|March 23, 2012

Summary

Adding amiodarone to a postoperative atrial fibrillation (AF) prevention pathway significantly reduced AF incidence by 45% and tended to decrease length of stay (LOS) in cardiac surgery patients.

More Related Videos

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: May 23, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Robotic Ablation of Atrial Fibrillation

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Cardiology
Cardiac Surgery
Pharmacology

Background:

Postoperative atrial fibrillation (AF) is a common complication after cardiac surgery.
Existing AF prevention protocols aim to mitigate this risk.
Investigating novel pharmacologic interventions is crucial for improving patient outcomes.

Purpose of the Study:

To evaluate the efficacy of incorporating amiodarone into an established postoperative AF prevention protocol.
To assess the impact of amiodarone on AF incidence and length of stay (LOS) in cardiac surgical patients.

Main Methods:

A prospective study comparing two groups of cardiac surgical patients (n=1068) over two consecutive periods.
One group received a standard AF prevention protocol; the second group received the same protocol with the addition of intraoperative and postoperative amiodarone.
Propensity score analysis was used to adjust for baseline differences between groups.

Main Results:

The addition of amiodarone resulted in a significant 45% reduction in postoperative AF incidence (16% vs. 29%, P < 0.0001).
Risk-adjusted analysis confirmed amiodarone's significant benefit in reducing AF (RR 0.65, P = 0.001).
While not statistically significant (P=0.06), patients on amiodarone experienced a trend towards reduced length of stay when AF occurred.

Conclusions:

Intraoperative and postoperative amiodarone administration significantly decreases the incidence of postoperative atrial fibrillation in cardiac surgery.
The amiodarone protocol showed a trend towards reducing length of stay in patients who developed AF.
Amiodarone is an effective adjunct to existing AF prevention strategies in the cardiac surgery population.